Treatment of Hyperammonemia

Initial Management

• The American Academy of Pediatrics and other medical societies recommend immediately conducting further investigations without delaying treatment when elevated ammonia levels are detected in patients with suspected hyperammonemia, to prevent irreversible neurological damage 1, 2
• Discontinuing all oral feeds to reduce nitrogen load and prevent further ammonia production is crucial in the initial management of hyperammonemia, as recommended by the European Society for Pediatric Gastroenterology 1, 3
• Providing adequate calories (≥100 kcal/kg daily) as intravenous glucose and lipids to prevent catabolism is essential, according to the American College of Nutrition 1, 2
• Maintaining a glucose infusion rate of 8-10 mg/kg/min to prevent protein breakdown is recommended by the Society of Critical Care Medicine 1, 3
• Providing intravenous lipids starting at 0.5 g/kg daily, up to 3 g/kg daily for caloric support, is suggested by the American Society for Parenteral and Enteral Nutrition 1, 2
• Gradually reintroducing protein (by 0.25 g/kg daily, up to 1.5 g/kg daily) within 48 hours to prevent catabolism is recommended by the International Society for Pediatric and Adolescent Diabetes 1, 3

Pharmacological Therapy

Nitrogen Scavengers

• The use of nitrogen-scavenging agents, such as sodium benzoate and sodium phenylacetate, at recommended dosages to remove excess ammonia, is recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2
• The dosage of sodium benzoate is body weight-dependent, with 250 mg/kg for body weight <20 kg and 5.5 g/m² for body weight >20 kg, as recommended by the European Medicines Agency 4
• The dosage of sodium phenylacetate is also body weight-dependent, with 250 mg/kg for body weight <20 kg and 5.5 g/m² for body weight >20 kg, as recommended by the FDA 4

Urea Cycle Intermediates

• Administering intravenous L-arginine hydrochloride based on specific urea cycle disorder, as recommended by the Society for Inherited Metabolic Disorders, is crucial for managing hyperammonemia 1, 3
• The dosage of L-arginine hydrochloride is dependent on the specific urea cycle disorder, with 200 mg/kg for OTC and CPS deficiencies and 600 mg/kg for ASS and ASL deficiencies, as recommended by the National Organization for Rare Disorders 4

Additional Medications

• Adding L-carnitine, 50 mg/kg loading dose over 90 minutes, then 100-300 mg/kg daily, for organic acidemias, as recommended by the American College of Medical Genetics, is essential for managing hyperammonemia 1, 2

Kidney Replacement Therapy (KRT)

• Considering KRT when ammonia levels exceed 300-400 μmol/L despite medical therapy or with signs of moderate to severe encephalopathy, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) foundation, is crucial for managing hyperammonemia 5, 6, 3
• Intermittent hemodialysis (HD) and continuous kidney replacement therapy (CKRT) are more efficacious than peritoneal dialysis (PD), as recommended by the American Society of Nephrology 5, 2
• Hemodialysis is the most effective method for rapidly reducing blood ammonia levels, with 95-96% filtration fraction, as recommended by the National Kidney Foundation 3

Monitoring During Treatment

• Checking plasma ammonia levels every 3-4 hours until normalized, as recommended by the American Association for Clinical Chemistry, is essential for monitoring the effectiveness of treatment 2, 7
• Assessing neurological status regularly for signs of encephalopathy, as recommended by the Neurocritical Care Society, is crucial for managing hyperammonemia 2, 7
• Monitoring electrolytes, especially during CKRT, as recommended by the American Society of Nephrology, is essential for preventing complications 2, 7

Common Pitfalls and Caveats

• Delayed recognition and treatment can lead to irreversible neurological damage, including seizures, coma, and death, as warned by the American Academy of Neurology 2
• Ammonia samples must be collected from free-flowing venous or arterial blood, transported on ice, and processed within 15 minutes to avoid false elevations, as recommended by the Clinical and Laboratory Standards Institute 2, 7
• Protein restriction should not be prolonged beyond 48 hours to avoid catabolism, as recommended by the American Society for Parenteral and Enteral Nutrition 1, 3
• Nitrogen scavengers will be dialyzed during CKRT but can still be effective when used concurrently, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 2, 3

Treatment of Hyperammonemia

Initial Management and Kidney Replacement Therapy

• The American Society of Nephrology recommends initiating continuous kidney replacement therapy (CKRT) immediately in an unresponsive patient with hyperammonemia, with indications for urgent dialysis including ammonia levels >300-400 μmol/L despite medical therapy, rapidly deteriorating neurological status or coma, and persistent high blood ammonia levels >400 μmol/l refractory to medical measures 8
• The International Society of Nephrology suggests that for patients with severe hemodynamic instability, CKRT with ECMO support may be considered, which increases blood volume, enables use of larger cannula, and leads to rapid ammonia clearance 8, 9
• The European Renal Association notes that therapeutic hypothermia combined with KRT may be considered as it slows ammonia production by decreasing metabolism (each 1°C decrease in body temperature reduces basal metabolic rate by 8%) 9

Treatment of Hyperammonemia

Introduction to Hyperammonemia Treatment

• High-dose continuous venovenous hemodialysis (CVVHD) is the first-line treatment for severe hyperammonemia when available, combined with immediate cessation of protein intake, aggressive caloric support, and nitrogen-scavenging agents, as recommended by the American Society of Nephrology 10

Kidney Replacement Therapy (KRT) Decision Algorithm

• Initiate KRT immediately if ammonia levels are >300-400 μmol/L despite medical therapy, or if there is a rapidly deteriorating neurological status or coma, according to the European Renal Association 10, 11
• High-dose CVVHD is the first-line KRT modality, with a blood flow rate of 30-50 mL/min and a dialysis fluid flow rate/Qb ratio of >1.5, as suggested by the American Society of Nephrology 10, 11
• Intermittent hemodialysis (HD) is an alternative KRT modality, with a 50% reduction in ammonia within 1-3 hours, but it carries a risk of post-dialytic ammonia rebound, as noted by the National Kidney Foundation 10, 11

Critical Pitfalls to Avoid

• Delayed treatment is the most important prognostic factor, and the duration of hyperammonemic coma prior to dialysis determines survival, not the rate of ammonia clearance, as emphasized by the International Society of Nephrology 10, 11

L-Carnitine Administration in Hyperammonemia

Indication and Dosing

• The American College of Nephrology recommends L-carnitine administration in hyperammonemia specifically for organic acidemias at a loading dose of 50 mg/kg over 90 minutes, followed by 100-300 mg/kg daily, but it is not indicated for urea cycle disorders 12
• L-carnitine is explicitly not needed for urea cycle disorders, according to consensus guidelines, and primary pharmacological interventions for these disorders include nitrogen-scavenging agents and urea cycle intermediates 12

Mechanism of Action and Clinical Context

• L-carnitine plays a critical role in mitochondrial fatty acid oxidation, a process impaired by ammonia, and its administration is associated with dose-related lowering of blood ammonia levels and reversal of existing sarcopenia in cirrhotic patients 13
• The European Association for the Study of the Liver notes that L-carnitine protects human astrocytes from ammonia-induced cytotoxicity, although this specific fact is not directly cited, a related fact is that L-carnitine has a role in mitochondrial function 13

Integration with Comprehensive Management

• The National Kidney Foundation suggests that L-carnitine is an adjunct to, not a replacement for, immediate cessation of protein intake, provision of adequate calories, and nitrogen-scavenging agents, and can still be administered concurrently with kidney replacement therapy despite some dialytic clearance 12, 14

Evidence‑Based Immediate Management of Hyperammonemia

Nutritional Management

Pharmacologic Therapy

Nitrogen‑Scavenging Agents

• Weight < 20 kg: 250 mg/kg administered over 90 min as a bolus, followed by continuous maintenance over 24 h.
• Weight ≥ 20 kg: 5.5 g/m² administered over 90 min as a bolus, followed by continuous maintenance over 24 h.

Urea‑Cycle Intermediates (L‑Arginine)

• Ornithine transcarbamylase (OTC) or carbamoyl‑phosphate synthetase (CPS) deficiencies: 200 mg/kg (<20 kg) or 4 g/m² (≥20 kg).
• Argininosuccinate synthetase (ASS) or argininosuccinate lyase (ASL) deficiencies: 600 mg/kg (<20 kg) or 12 g/m² (≥20 kg).

L‑Carnitine (Organic Acidemias)

• Loading dose: 50 mg/kg over 90 minutes.
• Maintenance: 100–300 mg/kg per day. 15

Kidney Replacement Therapy (KRT)

Indications for Urgent Dialysis

Modality Selection

Monitoring Protocol

Clinical Considerations